Claims for Patent: 9,822,182

Summary for Patent: 9,822,182

Title:	Anti-EPCAM antibodies and methods of use
Abstract:	The present disclosure is related to compositions of antibodies and immunoconjugates that potentially lack T-cell epitopes and elicit reduced immune response. The antibody may be an antibody fragment, such as Fab, Fab\', F(ab\')2, scFv, dsFv, ds-scFv, dimers, minibodies, diabodies, bispecific antibody fragments, multimers, and any combination thereof. In a further embodiment, the antibody may bind to an antigen epithelial cell adhesion molecule (EpCAM). In another embodiment, an immunoconjugate may comprise an antibody attached to an effector molecule, wherein the effector molecule may be a radioisotope, an antineoplastic agent, an immunomodulator, a biological response modifier, lectin, a toxin, a chromophore, a fluorophore, a chemiluminescent compound, an enzyme, a metal ion, and any combination thereof.
Inventor(s):	Cizeau; Jeannick (Winnipeg, CA), Premsukh; Arjune (Winnipeg, CA), Chooniedass; Shilpa (Winnipeg, CA), MacDonald; Glen (Winnipeg, CA), Entwistle; Joycelyn (Winnipeg, CA)
Assignee:	VIVENTIA BIO INC. (Winnipeg, Manitoba, CA)
Application Number:	15/026,834
Patent Claims:	1. An antibody that binds to epithelial cell adhesion molecule (EpCAM) comprising: a heavy chain having an amino acid sequence selected from SEQ ID NO: 1, SEQ ID NO: 11, SEQ ID NO: 31, and SEQ ID NO: 32, and a light chain having an amino acid sequence selected from SEQ ID NO: 2 and SEQ ID NO: 12. 2. An immunoconjugate comprising an antibody attached to an effector molecule, wherein the antibody binds to epithelial cell adhesion molecule (EpCAM) and comprises a heavy chain having an amino acid sequence selected from SEQ ID NO: 1, SEQ ID NO: 11, SEQ ID NO: 31, and SEQ ID NO: 32, and a light chain having an amino acid sequence selected from SEQ ID NO: 2 and SEQ ID NO: 12. 3. The immunoconjugate of claim 2, wherein the heavy chain has the amino acid sequence as shown in SEQ ID NO: 1 and the light chain has the amino acid sequence as shown in SEQ ID NO: 2. 4. The immunoconjugate of claim 2, wherein the heavy chain has the amino acid sequence as shown in SEQ ID NO: 11 and the light chain has the amino acid sequence as shown in SEQ ID NO: 12. 5. The immunoconjugate of claim 2, wherein the heavy chain has the amino acid sequence as shown in SEQ ID NO: 31 and the light chain has the amino acid sequence as shown in SEQ ID NO: 12. 6. The immunoconjugate of claim 2, wherein the heavy chain has the amino acid sequence as shown in SEQ ID NO: 32 and the light chain has the amino acid sequence as shown in SEQ ID NO: 12. 7. The immunoconjugate according to claim 2, wherein the antibody is an antibody fragment selected from the group consisting of Fab, Fab', F(ab')2, scFv, dsFv, ds-scFv, dimers, minibodies, diabodies, bispecific antibody fragments, non-immunoglobulin scaffolds, multimers, and any combination thereof. 8. The immunoconjugate according to claim 2, wherein the antibody is an antibody fragment Fab and wherein light chain and the heavy chain are linked by a covalent bond. 9. The immunoconjugate of claim 8, wherein the covalent bond is a disulfide bond. 10. The immunoconjugate according to claim 2, wherein the effector molecule is selected from the group consisting of a radioisotope, an antineoplastic agent, an immunomodulator, a biological response modifier, lectin, a toxin, a chromophore, a fluorophore, a chemiluminescent compound, an enzyme, a metal ion, and any combination thereof. 11. The immunoconjugate according to claim 2, wherein the effector molecule is a toxin selected from the group consisting of abrin, modeccin, viscumin, gelonin, bouganin, saporin, ricin, ricin A chain, bryodin, luffin, momordin, restrictocin, Pseudomonas exotoxin A, pertussis toxin, tetanus toxin, botulinum toxin, Shigella toxin, cholera toxin, diphtheria toxin, and any combination thereof. 12. The immunoconjugate according to claim 2, wherein the effector molecule is Pseudomonas exotoxin A (SEQ ID NO: 3). 13. The immunoconjugate according to claim 2, wherein the effector molecule is bouganin toxin (SEQ ID NO: 4). 14. The immunoconjugate according to claim 2, wherein the effector molecule is bouganin toxin selected from SEQ ID NO: 33, SEQ ID NO: 42, and SEQ ID NO: 43. 15. A composition comprising an immunoconjugate according to claim 2 and a pharmaceutically acceptable excipient, carrier, buffer or stabilizer. 16. A method of detecting or monitoring cancer in a subject comprising the steps of: contacting a test sample taken from the subject with an antibody according to claim 1 to form an antibody-antigen complex; measuring the amount of the antibody-antigen complex in the test sample; and normalizing the results against a control. 17. A method of imaging a tumor in a subject, the method comprising: administering to the subject an antibody according to claim 1; and detecting the antibody by in vivo imaging. 18. A method of treating a subject with cancer, the method comprising: administering to the subject a therapeutically effective amount of an immunoconjugate according to claim 2. 19. The method of claim 18, wherein the heavy chain has the amino acid sequence as shown in SEQ ID NO: 1 and the light chain has the amino acid sequence as shown in SEQ ID NO: 2. 20. The method of claim 18, wherein the heavy chain has the amino acid sequence as shown in SEQ ID NO: 11 and the light chain has the amino acid sequence as shown in SEQ ID NO: 12. 21. The method of claim 18, wherein the heavy chain has the amino acid sequence as shown in SEQ ID NO: 31 and the light chain has the amino acid sequence as shown in SEQ ID NO: 12. 22. The method of claim 18, wherein the heavy chain has the amino acid sequence as shown in SEQ ID NO: 32 and the light chain has the amino acid sequence as shown in SEQ ID NO: 12. 23. The method according to claim 18, wherein the antibody is an antibody fragment selected from the group consisting of Fab, Fab', F(ab')2, scFv, dsFv, ds-scFv, dimers, minibodies, diabodies, bispecific antibody fragments, non-immunoglobulin scaffolds, multimers, and any combination thereof. 24. The method according to claim 18, wherein the effector molecule is selected from the group consisting of a radioisotope, an antineoplastic agent, an immunomodulator, a biological response modifier, lectin, a toxin, a chromophore, a fluorophore, a chemiluminescent compound, an enzyme, a metal ion, and any combination thereof. 25. The method according to claim 18, wherein the administration of the immunoconjugate is by parenteral administration selected from the group consisting of subcutaneous, intramuscular, intraperitoneal, intracavity, intrathecal, intratumoral, transdermal and intravenous injection. 26. The method according to claim 18, wherein the immunoconjugate administration is at a dosage of about 0.01 mg/kg/dose to about 2000 mg/kg/dose. 27. The method according to claim 18, wherein the immunoconjugate is co-administered, concurrently administered, or sequentially administered with one or more anticancer agents. 28. The method of claim 27, wherein the anticancer agents are selected from tamoxifen, toremifen, raloxifene, droloxifene, iodoxyfene, megestrol acetate, anasfrozole, letrazole, borazole, exemestane, flutamide, nilutamide, bicalutamide, cyproterone acetate, goserelin acetate, luprolide, finasteride, herceptin, methotrexate, 5-fiuorouracil, cytosine arabinoside, doxorubicin, daunomycin, epirubicin, idarubicin, mitomycin-C, dactinomycin, mithramycin, cisplatin, carboplatin, melphalan, chlorambucil, busulphan, cyclophosphamide, ifosfamide, nitrosoureas, thiotephan, vincristine, taxol, taxotere, etoposide, teniposide, amsacrine, Irinotecan, topotecan, epothilones, Iressa, Tarceva, angiogenesis inhibitors, EGF inhibitors, VEGF inhibitors, CDK inhibitors, cytokines, Her1 and Her2 inhibitors, and monoclonal antibodies. 29. The method according to claim 18, wherein the cancer is selected from the group consisting of lung cancer, gastric cancer, renal cancer, thyroid cancer, breast cancer, bladder cancer, ovarian cancer, colorectal cancer, head and neck cancer, hepatocellular carcinoma, esophageal, pancreas, and prostate cancer.

Details for Patent 9,822,182

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	09/25/1998		2033-10-02
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	02/10/2017		2033-10-02